Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Current Hematologic Malignancy Reports|August 30, 2018
Clinical Validation of KIT Inhibition in Advanced Systemic MastocytosisJohn H Baird, Jason GotlibCurrent Opinion in Oncology|July 7, 2025
The evolving treatment paradigm of chimeric antigen receptor T-cell therapy in lymphomaPaolo Lopedote, John H BairdJournal of Intensive Care Medicine|October 30, 2023
A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the IntensivistShin Yeu Ong, John H BairdCase Reports in Hematology|March 21, 2019
An Unusual Cause of Epistaxis: Paranasal Sinus Myeloid SarcomaKaruna Dewan, John H Baird, Courtney B ShiresAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 10, 2023
COVID-19 and Other Viral Infections in Patients With Hematologic MalignanciesCourtney E Harris, Abi Vijenthira, Shin Yeu Ong, et al.Blood Advances|July 28, 2019
A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosisJason Gotlib, John H Baird, Tracy I George, et al.British Journal of Haematology|November 8, 2014
Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamideJohn H Baird, Caterina P Minniti, Jung-Min Lee, et al.Transplantation and Cellular Therapy|May 20, 2026
High incidence of cytomegalovirus infection in patients receiving standard of care CD19- or BCMA-targeted CAR T-cell therapies for hematologic malignanciesTamer Othman, John H Baird, Yan Wang, et al.Cell Metabolism|August 7, 2012
Inhibiting adipose tissue lipogenesis reprograms thermogenesis and PPARγ activation to decrease diet-induced obesityIrfan J Lodhi, Li Yin, Anne P L Jensen-Urstad, et al.Cancers|March 29, 2023
Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell LymphomaColton Ladbury, Savita Dandapani, Claire Hao, et al.Pageof 3